If you've spent any time in genetics or wellness circles this year, you've probably seen the number: 40% of at-home DNA test results are wrong. It gets thrown around a lot, usually stripped of context, usually used to argue that genetic testing in general can't be trusted.
The number is real. The conclusion most people draw from it isn't quite right. Here's the actual story — and why it matters more, not less, when you're choosing which test to trust with decisions about your health.
Where the 40% actually comes from
The study behind the statistic, published by researchers at Ambry Genetics, looked specifically at one thing: patients who took their raw, uninterpreted genetic data from a DTC test, ran it through a free or low-cost third-party interpretation tool, got a "you carry a disease-risk variant" result, and then sent that result to a clinical lab for confirmation. Of those, 40% turned out to be false positives — variants that simply weren't real, or that had been misclassified.
That's a serious problem. But notice what's actually being tested here: it isn't the DNA sequencing technology, and it isn't a company's own clinically validated health report. It's what happens when raw genetic data — explicitly labeled by the testing company as "not validated for medical use" — gets fed into a free online tool that compares it against public databases and spits out a verdict, with no laboratory oversight and no human genetic counselor anywhere in the process.
In other words: the sequencing usually isn't the weak link. The unsupervised interpretation is.
Why this matters more in India right now
Genomic and preventive health testing is having a real moment here — biomarker tracking, comprehensive health assessments, and preventive diagnostics are becoming mainstream priorities for urban professionals rather than a niche interest, and that demand is only accelerating heading into events like this August's Longevity Summit India. That's a good thing. It also means the market is filling up fast with options that range from rigorous clinical labs to bargain-bin kits that outsource interpretation to whatever's cheapest.
When the market moves that fast, the accuracy question stops being academic. It becomes the actual difference between a result that helps you make a real decision and one that sends you down a health scare — or worse, a false reassurance — based on nothing solid.
Four questions that actually separate a trustworthy test from a risky one
1. Is the lab accredited, and by whom? Look for recognized quality certifications — NABL or CAP accreditation is the baseline to expect from a genetic testing lab, not a nice-to-have. Accreditation means the lab's processes have been independently audited, not just self-reported.
2. Are you getting a clinically validated report, or raw data you're expected to interpret yourself? This is the single biggest fork in the road. A validated clinical report has been through quality-control filtering, variant classification, and lab review before it reaches you. Raw data is exactly what it sounds like — unfiltered output that includes low-confidence calls never meant to stand on their own.
3. Does a human ever look at your result — ideally a genetic counselor or clinician? Physicians consistently note that genomic testing delivers the most value in clinical settings, where results get interpreted in context and integrated with family history and presentation — not read in isolation. A concerning result with no professional interpretation attached is where false alarms and misunderstood variants tend to happen.
4. Does the company tell you what a variant of uncertain significance actually means? Genetics is full of "we found something, but we don't yet know if it matters." A trustworthy report says so plainly. A less careful one dresses uncertainty up as a definitive risk finding, because "definitive" sells better than "we're not sure yet."
The distinction almost no one explains: three very different kinds of "result"
Part of why the 40% statistic gets misread so often is that most people — understandably — think of a genetic result as one thing: either you "have the gene" or you don't. In reality, a report can contain at least three fundamentally different types of finding, and they carry completely different weight.
Pathogenic variants are the closest thing to what people picture when they hear "genetic result." These are specific, well-characterized changes in a single gene — like a BRCA1 mutation — with strong, established evidence linking them to disease risk. They're rare, they're usually high-impact, and they're the category the 40% false-positive study was actually about. Getting this one wrong is the scenario worth being most careful around, which is exactly why it needs clinical confirmation, not a raw-data upload.
Variants of uncertain significance (VUS) are changes in a gene that have been detected, but where there isn't yet enough evidence to say whether they're harmless or harmful. This is not a weaker version of a pathogenic result — it's a different category entirely, and on its own a VUS should never drive a medical decision. A trustworthy report tells you plainly "we don't know yet" instead of quietly rounding uncertainty up to risk.
Polygenic risk scores (PRS) are a different tool altogether. Instead of looking at one gene with a large effect, a PRS combines the small, individually modest effects of hundreds or thousands of common variants across the genome to estimate someone's relative risk for a complex condition — things like type 2 diabetes or coronary artery disease, where genetics is one contributor among many alongside diet, activity, and environment. A PRS isn't a diagnosis and was never meant to be one. It's a probability shift, and its entire value is in prevention: it tells you whether you're the kind of person who'd benefit from earlier or more frequent screening, not whether you will or won't get a disease.
Treating a PRS like a pathogenic-variant diagnosis — or treating a VUS like a confirmed risk — is where a lot of the internet's genetic testing anxiety actually comes from. It isn't that any of these tools are unreliable on their own terms. It's that conflating three different kinds of evidence into a single "your DNA says X" headline erases exactly the nuance that made the finding useful in the first place. Part of what a clinically reviewed report — and a conversation with a genetic counselor — is for is keeping those three categories separate, instead of collapsing them into one number that sounds scarier or more certain than it actually is.
The takeaway isn't "don't trust genetic testing." It's "trust the right layer of it."
The 40% statistic is a real finding about a real failure mode — and it's worth taking seriously. But it's a failure mode specific to unsupervised raw-data interpretation, not a verdict on genetic testing as a category. A test built on an accredited lab, clinically validated reporting, and real human interpretation is a fundamentally different product than a raw data file run through a free browser tool — even if both started with the same cheek swab.
That distinction is exactly why we built Genomepatri, MedicaMap, and BRCAMap the way we did. MapMyGenome's team brings 26 years of genomics experience to the table, and we launched Genomepatri in 2013 as India's first preventive genomics test — years before "DNA testing" became a wellness buzzword. That track record comes with internally validated data, processing in NABL- and CAP-accredited labs, clinically reviewed reports, and a genetic counseling session included — not a spreadsheet of variants you're left to Google on your own.
Want to know what separates a clinically robust genetic report from a raw data dump? Explore how MapMyGenome's testing process works.
